Personalized mRNA melanoma vaccine shows clinical success, boosting platform prospects

A personalized mRNA vaccine for melanoma achieved clinical success, providing a much-needed boost for the mRNA platform after a period of setbacks. The result is a single trial outcome, and broader stability for mRNA in other therapeutic areas remains uncertain. This matters because it could revive investment and development in mRNA-based treatments beyond infectious disease.